Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.

PMID:
19729618
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.

Pinter A.

Curr HIV Res. 2007 Nov;5(6):542-53. Review.

PMID:
18045110
[PubMed - indexed for MEDLINE]
3.

GP120: target for neutralizing HIV-1 antibodies.

Pantophlet R, Burton DR.

Annu Rev Immunol. 2006;24:739-69. Review.

PMID:
16551265
[PubMed - indexed for MEDLINE]
4.

The implications of antigenic diversity for vaccine development.

Zolla-Pazner S, Gomy MK, Nyambi PN.

Immunol Lett. 1999 Mar;66(1-3):159-64. Review.

PMID:
10203049
[PubMed - indexed for MEDLINE]
5.

Epitopes of HIV-1 glycoproteins recognized by the human immune system.

Laal S, Zolla-Pazner S.

Chem Immunol. 1993;56:91-111. Review. No abstract available.

PMID:
7680869
[PubMed - indexed for MEDLINE]
6.

Neutralizing antibodies to HIV-1 induced by immunization.

McCoy LE, Weiss RA.

J Exp Med. 2013 Feb 11;210(2):209-23. doi: 10.1084/jem.20121827. Review.

PMID:
23401570
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.

Pollara J, Bonsignori M, Moody MA, Pazgier M, Haynes BF, Ferrari G.

Curr HIV Res. 2013 Jul;11(5):378-87. Review.

PMID:
24191939
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Haynes BF, Montefiori DC.

Expert Rev Vaccines. 2006 Jun;5(3):347-63. Review.

PMID:
16827619
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Improving on nature: focusing the immune response on the V3 loop.

Zolla-Pazner S.

Hum Antibodies. 2005;14(3-4):69-72. Review.

PMID:
16720976
[PubMed - indexed for MEDLINE]
10.

Structure-based vaccine design in HIV: blind men and the elephant?

Pejchal R, Wilson IA.

Curr Pharm Des. 2010;16(33):3744-53. Review.

PMID:
21128885
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM.

Hum Antibodies. 2005;14(3-4):59-67. Review.

PMID:
16720975
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Recent strategies targeting HIV glycans in vaccine design.

Horiya S, MacPherson IS, Krauss IJ.

Nat Chem Biol. 2014 Nov 13;10(12):990-999. doi: 10.1038/nchembio.1685. Review.

PMID:
25393493
[PubMed - as supplied by publisher]
13.

Antibody B cell responses in HIV-1 infection.

Mouquet H.

Trends Immunol. 2014 Nov;35(11):549-561. doi: 10.1016/j.it.2014.08.007. Epub 2014 Sep 16. Review.

PMID:
25240985
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk